Drug Prices

Compounding Pharmacy
Pharmalot

A compounder loses a battle with the FDA over using bulk substances

By Ed Silverman

Wyden Grassley
Politics

Senate committee unveils ambitious plan to cap drug price hikes, out-of-pocket expenses

By Lev Facher and Nicholas Florko

2018 Senate McCaskill
Politics

Former pharma hawk McCaskill: Drug pricing system is a ‘stinking stew of a mess’

By Lev Facher

Pharmalot

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

By Ed Silverman

U.S. Sen. Kamala Harris
Politics

Kamala Harris becomes the latest Democratic candidate to zero in on drug prices

By Lev Facher

Pharmalot

Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug

By Ed Silverman

Pharmacy Benefit Managers
Pharmalot

AIDS groups criticize Express Scripts for excluding several HIV medicines

By Ed Silverman

JOHNSON & JOHNSON HEADQUARTERS
Pharmalot

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

By Ed Silverman

Pharmalot

Generic drug price-fixing suit is akin to earlier case, but ‘on steroids,’ Conn. prosecutor says

By Ed Silverman

Antibiotics Pharmacy
Pharmalot

Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice

By Ed Silverman

Stark medication bottle
First Opinion

John Arnold: Trump administration’s good effort on drug rebates is bad policy

By John Arnold

Pharmalot

Pharmalittle: A Pfizer and Lilly painkiller misses study goals; LA County joins statewide effort to lower drug prices

By Ed Silverman

Eli Lilly insulin
Pharmalot

Lilly discloses pricing data on insulin in response to political pressure

By Ed Silverman

Jeffrey Leiden
Pharmalot

Vertex CEO says he will bring ‘new ideas’ to break a stalemate in the U.K. over a cystic fibrosis drug

By Ed Silverman

Hep C San Fran
Pharmalot

The ‘Netflix’ model for hepatitis C drugs is saving Australia a lot of money

By Ed Silverman

Racial bias Pain Management
Pharmalot

Lawmakers ask FDA to explain steps to contain contaminants in blood pressure drugs

By Ed Silverman

Vertex
Pharmalot

U.K. lawmaker challenges the government to issue a compulsory license for Vertex drug

By Ed Silverman

Jeffrey Leiden
Pharmalot

Vertex faces more pressure over pricing, but one analyst does not expect any movement

By Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan

By Ed Silverman

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

FDA Generic
Pharmalot

Canada ends a probe into three big drug makers accused of thwarting generic competition

By Ed Silverman

Drug costs
Pharmalot

Trump administration report would preclude reclaiming patents as a way to lower drug prices

By Ed Silverman

Pill illo
Pharmalot

As pharma seeks more orphan drug designations, FDA fails to assess important needed info

By Ed Silverman

Pharmalot

Pharmalittle: Merck boosts prices on a few drugs; former Insys execs pleads guilty in Subsys conspiracy

By Ed Silverman

Generic epinephrine
Pharmalot

FDA promised a ‘lower-cost option’ to EpiPen, but the price isn’t any lower

By Ed Silverman

Pharmalot

Pharmalittle: AbbVie sues U.K. over hepatitis C drug program; pharma braces for pricing proposals from Democrats

By Ed Silverman

Humira
Pharmalot

AbbVie offers a ‘huge’ discount on Humira to fend off European rivals

By Ed Silverman

Pharmalot

Pharmalittle: Trump to give speech today on drug pricing; FDA approves a novel, but pricey flu drug

By Ed Silverman

Clinical Trial pricing
Pharmalot

Here’s a hypothesis: Lower doses of some cancer pills could save a lot of money

By Ed Silverman

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy